Plus Therapeutics (NASDAQ:PSTV) treated the first patient in Part B (Cohort 4) of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of rhenium obisbemeda for the treatment of leptomeningeal metastases (LM) from solid tumors.
LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid and leptomeninges surrounding the brain and spinal cord.
“In Phase 1/Part B, we plan to dose escalate to the maximum tolerated single dose while simultaneously collaborating with the FDA to implement multiple dosing into the trial, ” Norman LaFrance, M.D., CMO of Plus, said in a statement.
The maximum total radiation activity administered in Phase 1/Part A was 26.4 millicuries. In Phase 1/Part B the maximum administered total radiation activity will be 110.0 millicuries in cohort 7.
